Santa Clara, Calif.-based Shockwave, which is developing a device to treat calcified coronary lesions with sonic pressure waves, said March 6 that it floated 5.7 million shares at $17 apiece, for gross proceeds of $96.9 million. The IPO includes a 30-day underwriters over-allotment option that could bring in another $14.5 million if fully exercised.
The company also said that Abiomed, which already has a stake in Shockwave, agreed to buy $10.0 million worth of SWAV shares at the $17-per-share IPO price. Shockwave last month set the float’s price range at $14 to $16 each for about 5 million shares.
The stock closed up 79.4% at $30.50 per share yesterday on the NASDAQ exchange.
Morgan Stanley and BofA Merrill Lynch were joint lead book-runners, with Wells Fargo Securities and Canaccord Genuity as co-managers. Perella Weinberg Partners acted as capital markets advisor.